Turnover: 759 million EUR (2023)
Country: France
Pharmaceutical laboratory belonging to the Servier group specializing in the production of generic drugs
News
Generic drugs: Biogaran strengthens its presence in pharmacies 07/03/2023
- The Laboratoires Servier subsidiary is France's number-one generics producer, ahead of its rival Viatris (ex-Mylan).
- Biogaran carries out 50% of its production at 40 sites in France, is listed in over 6,000 pharmacies out of 21,000, and generics account for 90% of its sales
- Biosimilars account for 1/3 of drugs sold in France.
- The penetration of generics has reached a ceiling of 23% in primary care, compared with 90% in hospitals
- The biological drugs market represents €4 billion, and only a third (1.4 billion) is "biosimilarizable" - i.e., their patents have expired.
- The share to be taken by generics is therefore enormous
- Biosimilars cost around 30% less than original molecules
The cry of alarm from generic manufacturers 03/10/2022
- Generics account for 40% of all drugs sold in France
- Generics generate savings of 2.5 billion a year
- Government aims to relocate drug production to Europe
- a dozen generics account for 350 million euros in sales
Financial Data
DUNS: 405113598
Legal Name: BIOGARAN
Address: 15 BD CHARLES DE GAULLE , 92700 COLOMBES
Number of employees: Entre 200 et 249 salariés (2020)
Capital: 4 000 000 EUR
Financial Data:
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Turnover | 903 117 079 | 884 027 490 | 882 075 966 | 805 118 602 | 726 706 025 | 703 985 324 | 655 627 857 |
| Gross margin (€) | 552 088 281 | 528 934 950 | 508 137 788 | 472 596 463 | 423 991 114 | 415 360 930 | - |
| EBITDA (€) | 81 801 880 | 79 679 845 | 87 301 269 | 85 994 416 | 62 014 320 | 55 786 666 | - |
| Operating profit (€) | 70 229 243 | 68 767 495 | 78 002 188 | 75 218 420 | 57 435 684 | 50 660 148 | - |
| Net profit (€) | 50 420 739 | 46 382 725 | 52 540 526 | 54 691 824 | 28 758 779 | 30 515 465 | 3 831 026 |
| Turnover growth rate (%) | 2,2 | 0,2 | 9,6 | 10,8 | 3,2 | 7,4 | - |
| Ebitda margin rate (%) | 9,1 | 9 | 9,9 | 10,7 | 8,5 | 7,9 | - |
| Operating margin rate (%) | 7,8 | 7,8 | 8,8 | 9,3 | 7,9 | 7,2 | - |
| Working Capital (turnover days) | 94,4 | 94,8 | 96,9 | 100,7 | 87,6 | 81,6 | - |
| Working Capital requirements (turnover days) | 55,9 | 61,2 | 59,8 | 54,2 | 59 | 56,3 | - |
| Net margin (%) | 5,6 | 5,2 | 6 | 6,8 | 4 | 4,3 | - |
| Added value / Turnover (%) | 14,1 | 13,9 | 14,7 | 15,1 | 13,2 | 12 | - |
| Wages and social charges (€) | 25 632 308 | 25 194 576 | 23 474 276 | 21 238 732 | 19 244 107 | 16 406 346 | - |
| Salaries / Turnover (%) | 2,8 | 2,8 | 2,7 | 2,6 | 2,6 | 2,3 | - |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Président | Pascal | BRIERE | 63 | |
| Directeur général | Jerome | WIROTIUS | 54 | |
| Directeur général délégué | Nathalie | WAGNER | 49 |